MGX
Metagenomi Therapeutics, Inc.
Price Chart
Latest Quote
$1.24
+0.05 (+4.20%)
Current Price
| Previous Close | $1.19 |
| Open | $1.16 |
| Day High | $1.26 |
| Day Low | $1.16 |
| Volume | 72,218 |
Stock Information
| Shares Outstanding | 37.65M |
| Total Debt | $39.19M |
| Cash Equivalents | $140.16M |
| Revenue | $22.33M |
| Net Income | $-85.89M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $45.18M |
| EPS (TTM) | $-2.29 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-54.29M |
| Sales | $22.33M |
| Income | $-85.89M |
| Book/sh | $3.66 |
| Cash/sh | $3.72 |
| Employees | 118 |
Financial Ratios
| Quick Ratio | 6.27 |
| Current Ratio | 6.42 |
| Debt/Eq | 28.44 |
Returns & Margins
| ROA | -23.44% |
| ROE | -49.02% |
| Operating Margin | -1970.11% |
Ownership
| Insider Ownership | 18.96% |
| Institutional Ownership | 19.32% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.82 |
| P/S | 2.02 |
| P/B | 0.33 |
Analyst Data
| Recommendation | none |
| Target Price | $8.00 |
Technical Indicators
| SMA20 | $1.26 |
| SMA50 | $1.34 |
| SMA200 | $1.73 |
| RSI | 34.15 |
| ATR | 0.0670 |
| Shares Float | 27.33M |
| Short Float | 6.00% |
| Short Ratio | 9.88 |
| Volatility | 0.65 |
| Rel Volume | 0.33 |
Performance History
| Week | +5.26% |
| Month | -11.11% |
| Quarter | -12.41% |
| 6 Months | -31.82% |
| YTD | -28.14% |
| Year | -15.49% |
| 10 Years | -88.36% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $1.20 | 50,486 |
| 2026-06-23 | $1.24 | 74,100 |
| 2026-06-22 | $1.19 | 94,200 |
| 2026-06-18 | $1.20 | 190,300 |
| 2026-06-17 | $1.18 | 100,100 |
| 2026-06-16 | $1.14 | 239,700 |
| 2026-06-15 | $1.17 | 326,900 |
| 2026-06-12 | $1.20 | 62,000 |
| 2026-06-11 | $1.25 | 53,600 |
| 2026-06-10 | $1.23 | 75,100 |
| 2026-06-09 | $1.23 | 174,000 |
| 2026-06-08 | $1.29 | 79,300 |
| 2026-06-05 | $1.28 | 274,600 |
| 2026-06-04 | $1.33 | 119,100 |
| 2026-06-03 | $1.33 | 151,800 |
| 2026-06-02 | $1.33 | 202,900 |
| 2026-06-01 | $1.31 | 171,200 |
| 2026-05-29 | $1.36 | 188,300 |
| 2026-05-28 | $1.40 | 208,700 |
| 2026-05-27 | $1.35 | 263,000 |
| 2026-05-26 | $1.36 | 162,000 |
About Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
đ° Latest News
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates
Simply Wall St. âĸ 2026-05-14T13:42:09Z
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-12T00:05:04Z
Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T21:15:02Z
Spotlight On 3 ASX Penny Stocks With Market Caps Under A$2B
Simply Wall St. âĸ 2026-04-02T20:02:23Z
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-03-05T22:30:03Z
Metagenomi Therapeutics: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-05T21:28:23ZAmphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Zacks âĸ 2026-02-26T22:30:02Z
Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?
Simply Wall St. âĸ 2026-02-12T10:47:50Z
Amazon Launches New AI Chip While Teasing Future Tech Collaboration With Nvidia
Investor's Business Daily âĸ 2025-12-02T17:26:40Z
Metagenomi, Ovid CEOs step aside; Cogent soars on âunprecedentedâ stomach cancer data
BioPharma Dive âĸ 2025-11-12T10:20:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $25,210,000 | $52,295,000 | $44,756,000 | $17,200,000 |
| Operating Revenue | $25,210,000 | $52,295,000 | $44,756,000 | $17,200,000 |
| Expenses | ||||
| Total Expenses | $121,223,000 | $141,196,000 | $123,248,000 | $61,840,000 |
| Other Income Expense | $-1,383,000 | $-9,392,000 | $2,796,000 | $295,000 |
| Other Non Operating Income Expenses | $-91,000 | $-207,000 | $-74,000 | $201,000 |
| Net Non Operating Interest Income Expense | $9,470,000 | $14,722,000 | $15,468,000 | $3,321,000 |
| Operating Expense | $121,223,000 | $141,196,000 | $123,248,000 | $61,840,000 |
| General And Administrative Expense | $26,790,000 | $32,017,000 | $28,845,000 | $18,701,000 |
| Interest Expense | - | - | $0 | $98,000 |
| Interest Expense Non Operating | - | - | $0 | $98,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-87,868,000 | $-78,058,000 | $-68,255,000 | $-43,593,000 |
| Net Interest Income | $9,470,000 | $14,722,000 | $15,468,000 | $3,321,000 |
| Interest Income | $9,470,000 | $14,722,000 | $15,468,000 | $3,419,000 |
| Normalized Income | $-86,577,292 | $-69,479,210 | $-70,522,300 | $-43,667,260 |
| Net Income From Continuing And Discontinued Operation | $-87,868,000 | $-78,058,000 | $-68,255,000 | $-43,593,000 |
| Total Operating Income As Reported | $-96,013,000 | $-88,901,000 | $-78,492,000 | $-44,640,000 |
| Net Income Common Stockholders | $-87,868,000 | $-78,058,000 | $-68,255,000 | $-43,593,000 |
| Net Income | $-87,868,000 | $-78,058,000 | $-68,255,000 | $-43,593,000 |
| Net Income Including Noncontrolling Interests | $-87,868,000 | $-78,058,000 | $-68,255,000 | $-43,593,000 |
| Net Income Continuous Operations | $-87,868,000 | $-78,058,000 | $-68,255,000 | $-43,593,000 |
| Pretax Income | $-87,926,000 | $-83,571,000 | $-60,228,000 | $-41,024,000 |
| Interest Income Non Operating | $9,470,000 | $14,722,000 | $15,468,000 | $3,419,000 |
| Operating Income | $-96,013,000 | $-88,901,000 | $-78,492,000 | $-44,640,000 |
| Per Share | ||||
| Diluted EPS | $-2.36 | $-2.36 | $-1.82 | $-1.45 |
| Basic EPS | $-2.36 | $-2.36 | $-1.82 | $-1.45 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,292 | $-606,210 | $602,700 | $19,740 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-89,404,000 | $-74,309,000 | $-77,155,000 | $-39,287,000 |
| Total Unusual Items | $-1,292,000 | $-9,185,000 | $2,870,000 | $94,000 |
| Total Unusual Items Excluding Goodwill | $-1,292,000 | $-9,185,000 | $2,870,000 | $94,000 |
| Reconciled Depreciation | $5,317,000 | $5,407,000 | $4,207,000 | $1,733,000 |
| EBITDA (Bullshit earnings) | $-90,696,000 | $-83,494,000 | $-74,285,000 | $-39,193,000 |
| EBIT | $-96,013,000 | $-88,901,000 | $-78,492,000 | $-40,926,000 |
| Diluted Average Shares | $37,251,050 | $33,027,889 | $37,527,695 | $29,964,395 |
| Basic Average Shares | $37,251,050 | $33,027,889 | $37,527,695 | $29,964,395 |
| Diluted NI Availto Com Stockholders | $-87,868,000 | $-78,058,000 | $-68,255,000 | $-43,593,000 |
| Tax Provision | $-58,000 | $-5,513,000 | $8,027,000 | $2,569,000 |
| Gain On Sale Of Security | $-1,292,000 | $-9,185,000 | $2,870,000 | $94,000 |
| Research And Development | $94,433,000 | $109,179,000 | $94,403,000 | $43,139,000 |
| Selling General And Administration | $26,790,000 | $32,017,000 | $28,845,000 | $18,701,000 |
| Other Gand A | $26,790,000 | $32,017,000 | $28,845,000 | $18,701,000 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $158,596,000 | $234,857,000 | $-135,584,000 | $-74,428,000 |
| Total Assets | $221,103,000 | $324,599,000 | $364,842,000 | $414,486,000 |
| Total Non Current Assets | $55,565,000 | $66,639,000 | $86,569,000 | $47,587,000 |
| Other Non Current Assets | $6,029,000 | $5,535,000 | $10,740,000 | $6,073,000 |
| Current Assets | $165,538,000 | $257,960,000 | $278,273,000 | $366,899,000 |
| Other Current Assets | $4,434,000 | $8,396,000 | $4,640,000 | $3,494,000 |
| Receivables | $305,000 | $1,257,000 | $2,451,000 | $1,274,000 |
| Accounts Receivable | $305,000 | $1,257,000 | $2,451,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $160,799,000 | $248,307,000 | $271,182,000 | $362,131,000 |
| Cash And Cash Equivalents | $41,722,000 | $27,386,000 | $140,603,000 | $184,441,000 |
| Non Current Prepaid Assets | - | - | $368,000 | $450,000 |
| Non Current Deferred Assets | - | - | $5,124,000 | $0 |
| Prepaid Assets | - | - | - | $685,000 |
| Other Receivables | - | - | - | $1,274,000 |
| Taxes Receivable | - | - | - | $289,000 |
| Accrued Interest Receivable | - | - | - | $261,000 |
| Debt | ||||
| Total Debt | $40,657,000 | $45,778,000 | $48,229,000 | $18,571,000 |
| Long Term Debt And Capital Lease Obligation | $34,632,000 | $40,186,000 | $44,802,000 | $17,056,000 |
| Current Debt And Capital Lease Obligation | $6,025,000 | $5,592,000 | $3,427,000 | $1,515,000 |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $62,507,000 | $89,742,000 | $500,426,000 | $488,914,000 |
| Total Non Current Liabilities Net Minority Interest | $39,574,000 | $52,433,000 | $431,565,000 | $440,377,000 |
| Other Non Current Liabilities | $1,953,000 | $2,010,000 | $5,079,000 | $1,033,000 |
| Non Current Deferred Liabilities | $2,989,000 | $10,237,000 | $30,926,000 | $76,185,000 |
| Current Liabilities | $22,933,000 | $37,309,000 | $68,861,000 | $48,537,000 |
| Current Deferred Liabilities | $8,700,000 | $22,762,000 | $48,905,000 | $34,685,000 |
| Payables And Accrued Expenses | $3,214,000 | $3,609,000 | $9,266,000 | $7,518,000 |
| Payables | $1,489,000 | $533,000 | $5,057,000 | $3,547,000 |
| Accounts Payable | $1,489,000 | $533,000 | $1,791,000 | $2,011,000 |
| Total Tax Payable | - | $0 | $3,266,000 | $1,536,000 |
| Income Tax Payable | - | $0 | $3,266,000 | $1,536,000 |
| Equity | ||||
| Common Stock Equity | $158,596,000 | $234,857,000 | $-135,584,000 | $-74,428,000 |
| Total Equity Gross Minority Interest | $158,596,000 | $234,857,000 | $-135,584,000 | $-74,428,000 |
| Stockholders Equity | $158,596,000 | $234,857,000 | $-135,584,000 | $-74,428,000 |
| Gains Losses Not Affecting Retained Earnings | $260,000 | $709,000 | $-97,000 | $-274,000 |
| Other Equity Adjustments | $260,000 | $709,000 | $-97,000 | $-274,000 |
| Retained Earnings | $-310,870,000 | $-223,002,000 | $-144,944,000 | $-76,689,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $350,758,000 | $346,103,000 |
| Other | ||||
| Ordinary Shares Number | $37,620,668 | $37,418,470 | $37,527,695 | $37,527,695 |
| Share Issued | $37,620,668 | $37,418,470 | $37,527,695 | $37,527,695 |
| Tangible Book Value | $158,596,000 | $234,857,000 | $-135,584,000 | $-74,428,000 |
| Invested Capital | $158,596,000 | $234,857,000 | $-135,584,000 | $-74,428,000 |
| Working Capital | $142,605,000 | $220,651,000 | $209,412,000 | $318,362,000 |
| Capital Lease Obligations | $40,657,000 | $45,778,000 | $48,229,000 | $18,571,000 |
| Total Capitalization | $158,596,000 | $234,857,000 | $-135,584,000 | $-74,428,000 |
| Additional Paid In Capital | $469,202,000 | $457,146,000 | $9,457,000 | - |
| Capital Stock | $4,000 | $4,000 | $0 | $2,535,000 |
| Common Stock | $4,000 | $4,000 | $0 | $2,535,000 |
| Preferred Stock | $0 | $0 | $0 | - |
| Non Current Deferred Revenue | $2,989,000 | $10,237,000 | $30,926,000 | $76,185,000 |
| Long Term Capital Lease Obligation | $34,632,000 | $40,186,000 | $44,802,000 | $17,056,000 |
| Current Deferred Revenue | $8,700,000 | $22,762,000 | $48,068,000 | $33,942,000 |
| Current Capital Lease Obligation | $6,025,000 | $5,592,000 | $3,427,000 | $1,515,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,994,000 | $5,346,000 | $7,263,000 | $4,819,000 |
| Current Accrued Expenses | $1,725,000 | $3,076,000 | $4,209,000 | $3,971,000 |
| Investments And Advances | $2,154,000 | $3,447,000 | $10,676,000 | $7,806,000 |
| Net PPE | $47,382,000 | $57,657,000 | $65,153,000 | $33,258,000 |
| Accumulated Depreciation | $-15,961,000 | $-11,269,000 | $-6,434,000 | $-2,248,000 |
| Gross PPE | $63,343,000 | $68,926,000 | $71,587,000 | $35,506,000 |
| Leases | $4,392,000 | $4,375,000 | $3,831,000 | $3,531,000 |
| Construction In Progress | $0 | $143,000 | $2,346,000 | $1,402,000 |
| Other Properties | $57,332,000 | $62,997,000 | $64,388,000 | $30,191,000 |
| Machinery Furniture Equipment | $1,619,000 | $1,411,000 | $1,022,000 | $382,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $119,077,000 | $220,921,000 | $130,579,000 | $177,690,000 |
| Total Partnership Capital | - | - | $-135,584,000 | $-74,428,000 |
| Limited Partnership Capital | - | - | $9,457,000 | $2,535,000 |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-89,466,000 | $-112,187,000 | $-101,223,000 | $15,747,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-88,892,000 | $-109,073,000 | $-91,409,000 | $29,724,000 |
| Cash Flow From Continuing Operating Activities | $-88,892,000 | $-109,073,000 | $-91,409,000 | $29,724,000 |
| Investing Activities | ||||
| Capital Expenditure | $-574,000 | $-3,114,000 | $-9,814,000 | $-13,977,000 |
| Investing Cash Flow | $103,529,000 | $-88,157,000 | $45,734,000 | $-122,200,000 |
| Cash Flow From Continuing Investing Activities | $103,529,000 | $-88,157,000 | $45,734,000 | $-122,200,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $84,013,000 | $4,295,000 | $239,594,000 |
| Financing Cash Flow | $-356,000 | $84,013,000 | $1,012,000 | $239,594,000 |
| Cash Flow From Continuing Financing Activities | $-356,000 | $84,013,000 | $1,012,000 | $239,594,000 |
| Net Other Financing Charges | $-558,000 | - | $-3,283,000 | - |
| Net Common Stock Issuance | $0 | $84,013,000 | $0 | - |
| Common Stock Issuance | $0 | $84,013,000 | $0 | - |
| Net Preferred Stock Issuance | - | $0 | $4,295,000 | $239,594,000 |
| Preferred Stock Issuance | - | $0 | $4,295,000 | $239,594,000 |
| Other | ||||
| End Cash Position | $46,915,000 | $32,634,000 | $145,851,000 | $190,514,000 |
| Beginning Cash Position | $32,634,000 | $145,851,000 | $190,514,000 | $43,396,000 |
| Changes In Cash | $14,281,000 | $-113,217,000 | $-44,663,000 | $147,118,000 |
| Proceeds From Stock Option Exercised | $202,000 | $0 | - | - |
| Net Investment Purchase And Sale | $104,066,000 | $-85,043,000 | $55,548,000 | $-108,223,000 |
| Sale Of Investment | $170,474,000 | $221,377,000 | $263,644,000 | $106,627,000 |
| Purchase Of Investment | $-66,408,000 | $-306,420,000 | $-208,096,000 | $-214,850,000 |
| Net PPE Purchase And Sale | $-537,000 | $-3,114,000 | $-9,814,000 | $-13,977,000 |
| Sale Of PPE | $37,000 | $0 | - | - |
| Purchase Of PPE | $-574,000 | $-3,114,000 | $-9,814,000 | $-13,977,000 |
| Change In Working Capital | $-22,094,000 | $-59,668,000 | $-26,429,000 | $69,487,000 |
| Change In Other Working Capital | $-21,098,000 | $-46,804,000 | $-30,297,000 | $65,661,000 |
| Change In Other Current Liabilities | $-5,673,000 | $-6,470,000 | $2,860,000 | $952,000 |
| Change In Payables And Accrued Expense | $-588,000 | $-5,265,000 | $3,275,000 | $6,786,000 |
| Change In Accrued Expense | $-1,642,000 | $-893,000 | $1,629,000 | $4,529,000 |
| Change In Payable | $1,054,000 | $-4,372,000 | $1,646,000 | $2,257,000 |
| Change In Account Payable | $1,054,000 | $-1,106,000 | $-84,000 | $721,000 |
| Change In Tax Payable | $0 | $-3,266,000 | $1,730,000 | $1,536,000 |
| Change In Income Tax Payable | $0 | $-3,266,000 | $1,730,000 | $1,536,000 |
| Change In Prepaid Assets | $4,313,000 | $-2,323,000 | $-1,090,000 | $-2,638,000 |
| Change In Receivables | $952,000 | $1,194,000 | $-1,177,000 | $-1,274,000 |
| Changes In Account Receivables | $952,000 | $1,194,000 | $-2,451,000 | $0 |
| Other Non Cash Items | $5,106,000 | $2,984,000 | $3,465,000 | $1,076,000 |
| Stock Based Compensation | $11,853,000 | $16,204,000 | $6,922,000 | $1,962,000 |
| Unrealized Gain Loss On Investment Securities | $1,292,000 | $9,185,000 | $-2,870,000 | $-94,000 |
| Asset Impairment Charge | $502,000 | $1,042,000 | $23,000 | $282,000 |
| Amortization Of Securities | $-3,000,000 | $-6,169,000 | $-8,472,000 | $-1,129,000 |
| Depreciation Amortization Depletion | $5,317,000 | $5,407,000 | $4,207,000 | $1,733,000 |
| Depreciation And Amortization | $5,317,000 | $5,407,000 | $4,207,000 | $1,733,000 |
| Depreciation | $5,317,000 | $5,407,000 | $4,207,000 | $1,733,000 |
| Net Income From Continuing Operations | $-87,868,000 | $-78,058,000 | $-68,255,000 | $-43,593,000 |
| Income Tax Paid Supplemental Data | - | $3,505,000 | $2,250,000 | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Change In Other Current Assets | - | - | - | $-173,000 |
Fetched: 2026-06-21